What Is Epithalon and How Does It Work
Epithalon (also written Epitalon) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG), developed by Dr. Vladimir Khavinson's laboratory at the St. Petersburg Institute of Bioregulation and Gerontology. It was designed as a simplified synthetic analog of epithalamin, a peptide-rich extract of the bovine pineal gland studied by the same research group as part of a multi-decade Russian program investigating short regulatory peptides and aging.
Epithalon's headline mechanism is telomerase activation. Telomerase is the enzyme that rebuilds the protective telomere caps on the ends of chromosomes, which normally shorten with each cell division. In laboratory experiments, Epithalon has been shown to induce expression of the catalytic subunit of telomerase (hTERT) and restore telomerase activity in cultured human cells that were previously telomerase-negative, resulting in measurable telomere elongation in that cell-culture system. Whether this translates into meaningful telomere extension in living human tissue has not been directly confirmed.
Research Dosing
There is no FDA-reviewed or clinically validated human dosing standard for Epithalon. The figures below reflect protocols associated with Khavinson's Russian research program and conventions commonly repeated across research-community sources - these are not the same as a peer-reviewed, placebo-controlled dosing trial.
| Dose | Course length | Frequency | Route |
|---|---|---|---|
| ~5–10mg/day (commonly cited range) | 10–20 consecutive days | 1–2 courses per year | SubQ injection |
Context: The short-course, once- or twice-yearly structure reflects the "geroprotector" dosing pattern associated with Khavinson's published research program rather than a continuous daily-use protocol. As with other figures in this table, treat this as a commonly cited convention rather than a clinically validated dose.
Regulatory Status
Epithalon is not an FDA-approved drug and is not currently listed in the FDA's 503A bulk drug substances list (21 CFR 216.23). As of mid-2026, an FDA advisory committee (the Pharmacy Compounding Advisory Committee) reviewed Epitalon-related bulk drug substances and issued a nonbinding favorable recommendation for further consideration - but this is not a final regulatory determination, and Epithalon has not been added to the approved bulks list as of this writing. Products sold as "Epithalon" - including the one carried in the BioStackIQ shop - are marketed and sold as research chemicals for laboratory and research use only, not for human consumption. Consult a qualified healthcare provider before considering any research compound protocol.
What Research Shows
The core evidence behind Epithalon's telomerase claim is a 2003 laboratory study from Khavinson's group, which added Epithalon to a culture of telomerase-negative human fetal fibroblasts and observed induced expression of the telomerase catalytic subunit, restored telomerase enzymatic activity, and telomere elongation in that cell population. A related follow-up study reported that Epithalon-treated fibroblast cultures underwent substantially more cell-division passages than untreated controls before reaching senescence. These are meaningful in vitro findings, but they are cell-culture results, not human clinical trial data - no published, controlled human trial has measured telomere length in living people before and after Epithalon administration, so claims of in-vivo human telomere extension remain unconfirmed.
For a broader look at how longevity-focused compounds are considered alongside other research peptides, see the peptides and anti-aging guide.